| 论文题目: | Plasma membrane gp96 enhances invasion and metastatic potential of liver cancer via regulation of uPAR |
|---|---|
| 作者: | Junwei Hou, Xin Li, Changfei Li, Lu Sun, Yulai Zhao, Jingmin* Zhao, and Songdong* Meng. |
| 联系作者: | |
| 刊物名称: | Mol Oncol |
| 期: | |
| 卷: | |
| 页: | |
| 年份: | 2015 |
| 影响因子: | 5.669 |
| 论文下载: | http://www.sciencedirect.com/science/article/pii/S1574789115000538 |
| 摘要: | Targeted therapy is currently under intensive investigation due to the resistance of liver cancer to cytotoxic chemotherapies. Dissecting the molecular events that drive the progression of liver cancer and defining specific targets are urgently needed to develop efficient tailored therapies. Cell membrane gp96 (mgp96) has been implicated in tumor growth and malignancy. Here, we explored the functional and clinical relevance of mgp96 in liver cancer. We found that elevated mgp96 abundance was associated with tumor metastasis and recurrence in patients with primary liver tumors. Decreased KDELR1 levels in hepatoma cells contribute to cell membrane translocation of the normally ER-resident gp96. Urokinase-type plasminogen activator receptor (uPAR) was identified as a mgp96 client protein, and mgp96 stabilized uPAR protein. Our clinical results proved that elevated mgp96 abundance is positively correlated with uPAR expression levels in liver tumors. We further provided evidence that targeting mgp96 with siRNA or a specific mAb that blocked the mgp96-uPAR interaction led to inhibited cell growth, survival, and invasion in vitro, as well as the suppression of liver tumor growth and metastasis in vivo. mgp96 promotes liver cancer progression through increasing the protein stability and signaling of uPAR, and may be a new promising target for suppressing uPAR-mediated tumor growth and metastasis in liver cancer. |
京公网安备 11010502044263号